Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)

Part of paid clinical trials in Portland, Oregon.

Sponsor
Oregon Health and Science University
Study ID
NCT03975153
Phase
PHASE2
Status
Completed

Conditions

  • Pityriasis Rubra Pilaris

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • guselkumab — BIOLOGICAL
    Treatment at the FDA-approved psoriasis dosing for 20 weeks

Study Details

15 patients with PRP will be treated with guselkumab for 20 weeks to determine safety and efficacy. Participants are required to travel to Portland, OR only for the first visit, week-4 visit, and week-24 visit. 3 visits in between these times and one follow up visit may be performed by secure videoconferencing.

Key Dates

Start date
Oct 3, 2019
Status verified
May 2024
Primary completion
Aug 11, 2022
Completion
Mar 22, 2024

Study Design

Enrollment
15 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: guselkumab treatment
    Treatment with guselkumab for 20 weeks

Primary Outcome Measure

Mean Change From Baseline Psoriasis Area and Severity Index (PASI) at Week-24 After Treatment With Guselkumab. [ Time Frame: 24 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Oregon Health and Science UniversityPortlandOregon97239-

Find similar trials in Portland, OR

By research site
Oregon Health and Science University· Portland, OR

Related Studies